Related Articles
A phase II, randomized study of aprepitant in the prevention of chemotherapy‑induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients
CISPLATIN-INDUCED ALTERATIONS OF SEROTONIN METABOLISM IN PATIENTS WITH OR WITHOUT EMESIS FOLLOWING CHEMOTHERAPY
ONDANSETRON VERSUS METOCLOPRAMIDE IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING - A METAANALYSIS
A multicentre, double-blind, randomised trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis
Difference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitant